We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Retroscreen | LSE:RVG | London | Ordinary Share | GB00B6ZM0X53 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 285.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 285.00 | GBX |
Retroscreen (RVG) Share Charts1 Year Retroscreen Chart |
|
1 Month Retroscreen Chart |
Intraday Retroscreen Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/9/2014 | 07:56 | Retroscreen Virology | 46 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 09/8/2013 07:28 by m.t.glass Retroscreen Virology Limited, the global leader in the conduct of Human Viral Challenge Studies, is pleased to announce that the Company will be attending the eighth Options for the Control of Influenza conference at The Cape Town International Convention Centre, Cape Town, South Africa, 4th-9th September 2013Held every 3 years, Options for the Control of Influenza is the largest international scientific conference exclusively devoted to influenza. See full article at EDIT: Share price up 123.6% since start of 2013. Up 236% since start of thread. Risky metrics though. |
Posted at 24/7/2013 21:29 by echelon Insti holdings are a pain in the A quite honestly. Once they decide to unload the "iceberg effect" can depress the price for weeks. I doubt they will be selling yet though, especially now that the co has attracted new funding. A promising co. |
Posted at 02/7/2013 07:15 by m.t.glass Yesterday, Invesco told us their stake is now increased to 20.2%. Today, Henderson Global Investors tell us they've taken their stake in RVG to 6.34% (last week it was trimmed to 4.75%) |
Posted at 14/6/2013 10:20 by fillipe £25m placing at £2....pretty big stuff.f |
Posted at 26/4/2013 10:52 by fillipe Coverage of RVG on the iii discussions is nil and similar on LSE.Today's 18% uptick (45p) adds almost £19m to the mkt cap and give a mkt cap of £118m.....you can't get better notice than that and all without any mentions or RNS's ! I think this goes beyond just testing, with something much greater in the tube. f |
Posted at 26/4/2013 10:26 by m.t.glass Haven't seen anything on my news alerts today so far. Share price is now up 100% since the start of 2013 |
Posted at 10/1/2013 14:19 by andrbea up 2%10/01/2013 13:49:41 RVG 175.00 O 5,000 10/01/2013 11:20:48 RVG 170.00 O 29,432 10/01/2013 11:20:33 RVG 170.00 O 25,000 10/01/2013 11:19:06 RVG 170.00 O 25,000 29432 at 170 is 50k pounds |
Posted at 10/1/2013 08:27 by m.t.glass No posts on this thread in June-through-Decembe |
Posted at 10/5/2012 21:53 by 2baffled Hi MT. Thank you for opening this forum.Interesting series of 'holdings notices' filtering through. I also note that IG have reasonable tier terms for RVG given it's a 'new-kid on the block'. [I too have IPO ....... FTSE 250 candidate, I believe]. IC comment [is it valid?] =====>> |
Posted at 03/5/2012 07:52 by m.t.glass I am not yet a buyer or holder of RVG shares - just watchin'I already hold shares in stakeholder IP Group (IPO) GCI yesterday: 02/05/2012 Ben Jaglom Pharma concern Retroscreen Virology Group is to join AIM this year in an IPO worth £15 million. The Tower-Hamlets based spin-out from Queen Mary University - which is hoping to raise the amount via broker Numis -specialises in viral studies in humans, developing drugs and vaccines for a variety of viral infections. Upon admission to the junior market at a price of 80p a share the group will have a market cap of circa £32.8 million. Retroscreen is being steered by chief executive officer Kym Denny, a veteran of the pharma sector and the former managing director of global research specialists Harrison Clinical Research. Overseeing action at Retroscreen is David Norwood, an ex-foreign exchange trader and the former CEO of stockbroker Beeson Gregory. Funds that have subscribed to the placing include Blackrock, Lansdown Partners and Henderson Global Investors. Shareholder Queen Mary University will see its stake diluted from 8.4 per cent to 4.5 per cent following admission. Joining at a tricky time for pharma companies on AIM, Retroscreen will have its work cut out convincing the market following the raft of disappointing IPOs that have emerged from the sector. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
